Navigation Links
Live-Attenuated Vaccines to Dominate Dengue Vaccine Market Through 2020, Says GlobalData in Its Report Published at MarketPublishers.com
Date:7/21/2014

London, UK (PRWEB) July 21, 2014

Deemed to be responsible for over 100 million infections each year, the dengue virus (DENV) is the world’s most prevalent arthropod-borne virus.

The live-attenuated vaccines, including Takeda's DENVax, Sanofi's CYD-TDV and the US National Institute of Health's TV-003, are expected to dominate the dengue vaccine marketplace through to 2020-end. In spite of lingering questions pertaining to their safety and ability to provide balanced short- to long-term protection against the 4 DENV serotypes, live-attenuation is regarded as the most promising technological approach to dengue vaccine R&D.

While the other classes of vaccines in clinical trials (subunit, inactivated virus and deoxyribonucleic acid vaccines) could theoretically reduce the chance of interference of viruses and be perceived as safer by patients, key opinion leaders predominantly treated them as inferior to live-attenuated vaccines and cited their need for adjuvants and late arrival to the market as major weak points. The live-attenuated dengue vaccines are projected to reach over USD 395 million in sales in 2020, posting a CAGR of 41.5% over the forecast period.

New research report “OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020” prepared by GlobalData is now available at MarketPublishers.com.

Report Details:

Title: OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020
Published: July, 2014
Pages: 188
Price: US$ 5,995.00
http://marketpublishers.com/report/pharmaceuticals/vaccines/opportunityanalyzer-dengue-vaccines-opportunity-analysis-n-forecasts-to-2020.html

The study canvasses the world dengue vaccine market, focusing on Brazil, India, Mexico, Singapore, and Thailand. It presents a brief overview of the disease (epidemiology, pathophysiology, aetiology, symptoms and existing treatment techniques); features annualised market revenue figures, yearly cost of therapy and treatment usage pattern data; provides a strategic analysis of leading products; characterises the overall market space; uncovers major unmet needs, canvasses R&D strategies, presents clinical studies information, gives an exhaustive pipeline analysis; and offers a clinical and commercial benchmarking survey of major pipeline vaccines. Furthermore, the research study provides an extensive evaluation of the competitive landscape (as of today and in the years to come), and is also enriched with a detailed analysis of the key restraints, drivers and challenges in the industry.

Report Highlights:

  •     Review of eetiology, epidemiology, symptoms, pathophysiology, diagnosis, and actual disease surveillance and preventive measures
  •     Key dengue vaccine market revenue forecast data during 2015-2020; annual cost of therapy and leading pipeline vaccine sales over the forecast period
  •     Strategic assessment of market competitors, market characterisation, research and development strategies, unmet needs, and clinical studies design
  •     Pipeline assessment, comprising comprehensive data split across various phases, emerging new trends under development, synopses of innovative early-stage projects, and granular analysis of late-stage pipeline vaccines
  •     In-depth examination of the actual and projected competition in the global dengue vaccine marketplace
  •     Coverage of key markets of Brazil, Mexico, India, Singapore, and Thailand

More new research reports by the publisher can be found at GlobalData page.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12033449.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Rising Incidence of Chronic Diseases in Children Drives the Pediatric Drugs and Vaccines Market, According to an Upcoming Report by Global Industry Analysts, Inc.
2. Study: When hospital workers get vaccines, community flu rates fall
3. Flu vaccines in schools limited by insurer reimbursement
4. One cell type may quash tumor vaccines
5. Study recalculates costs of combination vaccines
6. Radiation therapy and cancer vaccines: Timing is everything
7. Healthpointe Proudly Offers Flu Vaccines at All Clinics and On-Site to Businesses Throughout Southern California
8. Austin Doctor Participates in Flu Vaccine Research Study in an Effort to Find More Effective Vaccines.
9. Success of Vaccines Won’t Limit IVD Market: Kalorama Report
10. PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
11. HPV strains affecting African-American women differ from vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
Breaking Medicine Technology: